Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared a post on X:
“New Blood Advances treasure trove of data about bridging before CAR-T in MM. Bigger is not better when it comes to bridging using chemotherapy… Worse post-CAR-T efficacy (unsurprising: tumor biology as confounder) but also clearly worse cytopenias and infections!
In particular: the more chemo (“CTX”) drugs in any given bridging regimen, the worse & more persistent the post-CAR-T cytopenias. Also clear signal toward serious infections as well, which can drive MM NRM. Talq bridging may be a winner here!
And our accompanying Blood Advances commentary about this excellent work. Time to avoid the “burning bridges” of pre-CAR-T MM therapy and move to other bridges instead…”
Later He added a comment to the post:
“And excellent work by Fred Hutch Cancer Center trainee Swetha Reddi on accompanying Blood Advances commentary, including table summarizing 3 published analyses of this topic. Bottom line: if you’re thinking of PACE or hCVAD as bridging to MM CAR-T, may be time to think of something else!”
Title: Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma
Authors: Jan H. Frenking, Xiang Zhou, Kai Rejeski, Vivien Wagner, Patrick Costello, Thomas Hielscher, Lilan Gatti, Joseph Kauer, Omar Nadeem, Elias K. Mai, Christian S. Michel, Mirco J. Friedrich, David Sedloev, Niels Weinhold, Hartmut Goldschmidt, Klaus Herfarth, Anita Schmitt, Michael Hundemer, Michael Schmitt, Carsten Müller-Tidow, Max Topp, Hermann Einsele, Peter Dreger, Nikhil C. Munshi, Adam S. Sperling, Leo Rasche, Sandra Sauer, Marc S. Raab
More posts featuring Rahul Banerjee on OncoDaily.